Citius Oncology (CTOR) Change in Accured Expenses (2023 - 2026)

Citius Oncology's Change in Accured Expenses history runs 4 years deep, the most recent figure standing at $19.5 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 683.57% year-over-year to $19.5 million; the TTM figure through Mar 2026 stood at $15.3 million (up 70.01% YoY), while the FY2025 annual figure was $4.1 million, up 1679.92% from the prior year.
• Change in Accured Expenses was $19.5 million for Q1 2026 at Citius Oncology, up from $425792.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $19.5 million in Q1 2026 to a low of -$4.4 million in Q3 2025.
• Historically, Change in Accured Expenses has averaged $2.0 million across 4 years, with a median of $149139.5 in 2024.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses soared 3227.52% in 2024, then slumped 241.78% in 2025.
• A 4-year view of Change in Accured Expenses shows it stood at -$199155.0 in 2023, then jumped by 3227.52% to $6.2 million in 2024, then plunged by 93.16% to $425792.0 in 2025, then soared by 4488.78% to $19.5 million in 2026.
• The last three Change in Accured Expenses figures came in at $19.5 million (Q1 2026), $425792.0 (Q4 2025), and -$4.4 million (Q3 2025), per Business Quant data.